Lexicon Pharma (LXRX) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- What the Democratic sweep in the midterms means for markets
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.46 --0%
Revenue Growth %: -79.9%
Financial Fact:
Total operating expenses: 62.65M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: -79.9%
Financial Fact:
Total operating expenses: 62.65M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $160 thousand versus the consensus estimate of $2.06 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s posts better-than-expected third-quarter comparable sales
- XPEL, Inc. (XPEL) Tops Q3 EPS by 4c, Misses on Revenue; Offers Q4 Revenue Guidance
- Harmony Biosciences (HRMY) Misses Q3 EPS by 30c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
